**Name of Journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 57210

**Manuscript Type:** REVIEW

**Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic**

Naseer M *et al*. IBD management during COVID-19 pandemic

Maliha Naseer, Shiva Poola, Francis E Dailey, Hakan Akin, Veysel Tahan

**Maliha Naseer,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, East Carolina University, Greenville, NC 27834, United States

**Shiva Poola,** Department of Internal Medicine/Pediatrics, Brody School of Medicine/Vidant Medical Center, Greenville, NC 27834, United States

**Francis E Dailey, Hakan Akin, Veysel Tahan,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, Columbia, MO 65212, United States

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Corresponding author: Veysel Tahan, FACG, FACP, FEBG, MD, Assistant Professor,** Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO 65212, United States. tahanv@health.missouri.edu

**Received:** June 1, 2020

**Revised:** October 14, 2020

**Accepted:** October 26, 2020

**Published online:**

**Abstract**

Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic various measures have been taken to mitigate the effects of the global health crisis in this unpresented time. According to the World Health Organization, more than 5 million people have been infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and with more than 300000 deaths attributed to COVID-19 worldwide. There is emerging evidence that SARS-CoV-2 utilizes angiotensin-converting enzyme 2 receptors to enter human cells which are found in abundance in the alveoli and intestines. In addition, the infection is noted to be more severe in patients with co-morbid conditions, those who are malnourished, immunosuppressed and immunocompromised. Inflammatory bowel disease (IBD) which includes ulcerative colitis and Crohn’s disease is chronic remitting and relapsing disorders with intestinal and extraintestinal manifestation. IBD patients are often malnourished and on immunosuppressive medications and there is a hypothetical concern that IBD patients are at substantial risk of COVID-19 infection. The management of IBD patients is often complex and poses unique challenges for gastroenterologists during the pandemic. The purpose of this review article is to summarize the growing level of evidence and understanding of the management of IBD during the COVID-19 pandemic, in the light of international and national gastroenterology society guidelines. We performed a thorough literature search on IBD, SARS-CoV-2 and COVID-19 on PubMed, EMBASE, OVID Medline and Google Scholar and pertaining literature was critically examined and summarized. Per national and international society guidelines and recommendations, IBD is not a risk factor for SARS-CoV-2 infection. IBD patients should continue with their medications and they should follow universal precautions *i.e.* masks, hand and respiratory hygiene and avoidance of health care facilities and public toilets as general population. Among IBD patients older age, having active disease, and co-morbid conditions are risk factors for a severe SARS-CoV-2 infection. Furthermore, elective endoscopic and surgical procedures can be delayed or deferred until discussing the risks and benefits with patients.

**Key Words:** SARS-CoV-2; COVID-19; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Pandemic

Naseer M, Poola S, Dailey FE, Akin H, Tahan V. Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. *World J Meta-Anal* 2020; In press

**Core Tip:** The current pandemic caused by coronavirus disease 2019 (COVID-19) has resulted in devastating consequences worldwide. This viral infection affecting the respiratory and gastrointestinal systems is most severe in patients with co-morbid conditions, including the immunocompromised. Patients with inflammatory bowel disease are often malnourished and on immunosuppressive medications; management of this population poses unique challenges during this time. In this review, we summarize the current evidence and understanding of the management of inflammatory bowel disease during the COVID-19 pandemic. We further outline the current guidelines for treatment of those with inflammatory bowel disease and offer education for measures to prevent infections, including COVID-19.

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19), also known as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, is a global health emergency with major public health concerns[1]. SARS-COV is a single-stranded RNA virus belonging to the genus Betacoronavirus and subgenus Sarbecoronavirus and recognized to cause severe acute respiratory syndrome for two decades. SARS-COV is an emerging zoonotic disease that has the potential to infect humans, bats, and other mammals. There are hundreds of strains of the coronaviruses and over the last two decades different strains have caused three major documented epidemics globally, resulting in significant morbidity and mortality[2]. The current pandemic began at the end of 2019 as a cluster of new atypical pneumonia cases from an unknown cause, traced back to a wet animal market in the city of Wuhan, in the Hubei province in China. On December 31, 2019, the outbreak was reported to the WHO regional office in China and was linked to a novel strain of a coronavirus provisionally named as 2019-nCoV[3]. It was later designated as SARS-CoV-2 by the International Committee on Taxonomy of Viruses[4]. The SARS-CoV-2 virus rapidly spread in the entire world. As of October 9, 2020, there have been 36754395 confirmed cases of SARS-CoV-2 have been documented in over 187 countries and territories with a global death toll of 1064838. The first case of SARS-CoV-2 was reported in the United States of America (USA) on January 20, 2020, and since then the number of confirmed cases has been increased dramatically[5]. According to the Centers for Disease Control and Prevention (CDC) report from the USA, the overall cumulative hospitalization rate is 183.2 per 100000, with the highest rates in people 65 years and older (495.5 per 100000) and 50-64 years (273.2 per 100000)[6]. Other risk groups to get severe infection and hospital admission include male gender, smokers, residents at nursing home or long term care facilities, and people of all ages with pre-existing medical illness, *e.g.* hypertension, diabetes mellitus, obesity, chronic lung/liver/heart disease, chronic kidney disease undergoing dialysis, and immunocompromised or immunosuppressed patients[7].

Inflammatory bowel disease (IBD) which includes ulcerative colitis (UC) and Crohn’s disease (CD) is chronic remitting and relapsing disorders with intestinal and extraintestinal manifestation[8]. Globally, there are 6.8 million cases of IBD, and the age-standardized prevalence rate increased from 79.5/100000 population to 84.3/100000 population between 1990-2017[9]. There is evidence from translation research that angiotensin-converting enzyme 2 and TMPRS2 receptors are exhibited in abundance in ileum and colon[10] which leads to hypothesis that patients with CD and UC are more at risk of SARS-CoV-2 infection and its complications than general public. Furthermore, patients with IBD are usually malnourished and often treated with immunomodulators and immunosuppressive medications to control inflammation and prevent relapse and complications. These medications are known to be associated with opportunistic infections, particularly viral infections such as influenza and herpes zoster, with anti-tumor necrosis factors (anti-TNFs) reactivation of chronic hepatitis B, and viral warts associated with the use of thiopurines[11]. In addition, frequent encounters with health care facilities for infusion of the biologics, follow up visits, blood draws and endoscopies put these patients at risk for exposure to SARS-COV-2 infection. As a result, there is a concern among healthcare providers and patients that having IBD (quiescent or active) and medical therapies to control inflammation places them at substantial risk to contract SAR-CoV-2 infection, progression to a more critical illness such as intensive care unit (ICU) admission, ventilator use and an increased mortality than general population. However, there is strong evidence that having inflammatory bowel disease is not a risk factor for SARS-Cov-2 infection[12]. The management of IBD is complex, multifaceted and there are numerous questions and concerns related to IBD and COVID-19. The purpose of this review article is to summarize the growing level of evidence and understanding of the management of IBD during the COVID-19 pandemic, in the light of international and national gastroenterology society guidelines. To fulfil the objectives of the review, we did thorough literature search on PubMed, OVID and EMBASE through December 2019 to October 2020.

**PRESENTATION, CHARACTERITICS AND RISK FACTORS OF SEVERE COVID-19 INFECTION IN IBD PATIENTS**

The current literature suggests that digestive symptoms such as non-bloody diarrhea, nausea and vomiting are commonly exhibited by COVID-19 patients with a variable frequency of 11%-35%[13,14]. Nobel *et al*[15] published a case control study involving two-hundred and seventy-eight SARS-CoV-2 patients. According to the study results, patients with diarrhea, nausea and vomiting at the time of diagnosis of SARS-CoV-2 were 70% more likely to be tested positive for COVID-19 infection than other. Another retrospective cross-sectional study which included 207 consecutive patients with positive SARS-CoV-2 showed that the presence of digestive symptoms was associated with a higher severity of overall illness and the need of hospitalization. However, no significant differences were reported in ICU admissions, ventilator use and mortality in patients with predominantly gastrointestinal symptoms[16]. It is also now well established that there is fecal shedding of the coronavirus as detected by nucleic acid in more than 50% of patients’ stool samples and persists even after nasopharyngeal samples becomes negative[17]. Recently, a case of a female patient with COVID-19 infection presenting as bloody diarrhea was published by Carvalho *et al*[18] Her evaluation was significant for leukocytosis, elevated C-reactive protein and evidence of colitis on computed tomography (CT) scan of the abdomen. With the presumed diagnosis of infectious colitis and to rule out inflammatory and ischemic colitis, flexible sigmoidoscopy was performed which showed erythema without ulceration in the distal colon. Biopsies were negative for infectious colitis, ischemia, or inflammatory bowel disease. On day 4 of hospitalization, SARS-CoV-2 PCR from nasopharyngeal swab turned positive[18]. The clinical implication of these gastrointestinal symptoms is important especially in patients with IBD. Patients with IBD having new or worsening gastrointestinal symptoms with and without respiratory symptoms should be thoroughly evaluated using appropriate testing and non-invasive measure such as inflammatory markers, fecal calprotectin and imaging studies to differentiate acute flare with SARS-CoV-2 infection. In a systematic review published by D’Amico *et al*[19], the prevalence of COVID-19 in IBD cohort was found to be 0.4%. They included 23 studies and found more prevalence of COVID-19 infection in male patient with inflammatory bowel disease regardless of their age[19].

Patients with CD and UC are often immunosuppressed. However, the exact impact of the degree of immunosuppression on the severity of SARS-CoV-2 infection is not known. It is also not certain if the untreated or partially treated IBD increases the risk of getting SARS-CoV-2. Preliminary data of risk and characteristics of corona virus infection in IBD patients from the first epicenter i.e. Wuhan, China is scarce. A study published by An *et al*[20] included 318 patients with IBD registered between Jan 1, 2000, and Dec 8, 2019, in a prospective database were followed during the COVID-19 pandemic. Patients with IBD were contacted and educated about self-prevention measures such as hand hygiene, keeping track of pulmonary symptoms and fever and to seek medical assistance online *vs* in person. In addition, infliximab infusions and other immunosuppressive treatments were discontinued as per guidelines of the National Chinese Society of Gastroenterology[20]. In contrary, clinicians from Italy published their experience of managing seventy-nine patients with IBD who tested positive for COVID-19 from 24 referral IBD units from March 11-29, 2020. Of these patients, 28% of those with IBD and COVID-19 positive were hospitalized and another 6% were diagnosed with COVID-19 infection when they admitted in the hospital with IBD flares. After control of confounding factors, age more than 65 years, diagnosis of UC, IBD activity and Charlson Comorbidity Index > 1 were significantly associated with severe SARS-CoV-2 infection and hospitalization. In this study, the authors found no relation of IBD treatments with COVID-19 infection severity[21].

More recently, an international registry/database developed called Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-IBD to report adult and pediatric SARS-CoV-2 cases and its outcome in terms outpatient management *vs* hospitalization, ICU admission, ventilator use and mortality in IBD patients. As of October 10, 2020, 2575 cases of IBD disease with concurrent COVID-19 patients were reported to the registry worldwide. Preliminary analysis of this database showed that young (under 40 years) IBD patients with COVID-19 infection are more likely to exhibit a milder form of disease and approximately 80% were managed in the outpatient setting. There is a direct correlation of increasing age with more severe pneumonia requiring hospitalization, ICU admission and ventilator use. Approximately 25% of the deaths were reported in the older IBD patient *i.e.* ≥ 80 years which is highest among all age groups. Further, 54% of the male IBD and COVID-19-positive patients needed hospital admission, and 5% of developed severe respiratory disease as defined by ICU admission, ventilator use or even death. A total of 1447 patients with CD developed COVID-19 infection, and 78% of them were managed in the outpatient; of those with UC and COVID-19-positive, 70% were managed as outpatients. Those with UC were also more likely to develop severe disease, be admitted to the ICU, and require ventilator support. In terms of disease activity, IBD patients in remission who developed COVID-19 infection were more likely to develop a milder form of the viral illness, while those with moderate-to severe activity tended to be hospitalized and require ICU admission. Similarly, having multiple comorbid conditions was shown to be a risk factor for developing severe COVID-19 infection in those with underlying IBD[22].

**MANAGEMENT OF IBD MEDICATIONS DURING THE COVID-19 PANDEMIC**

The Crohn’s and Colitis Foundation of America (CCFA), the European Crohn’s and Colitis Organization (ECCO), and the International Organization for the study of Inflammatory Bowel Disease (IOIBD), recommend against discontinuation of immunosuppressive and biological drugs as a preventative strategy in IBD patients without symptoms and signs suggestive of COVID-19 infection[23-25]. In this section, we will discuss the safety of the medications (immunomodulators and immunosuppressive) in stable IBD patients without COVID-19 infection (Table 1).

***Sulfasalazine and 5-aminosalicylates***

Sulfasalazine and 5-aminosalicylates (5-ASA) are mild immunosuppressive medications and often used as initial therapy for induction and maintenance of mild to moderate UC[26]. Overall, they are safe, effective and tolerated well. Preliminary data from the SECURE-IBD registry showed about 14% of IBD and COVID-positive patients on sulfasalazine and 5-ASA compounds developed severe infection (ICU/Ventilator/Death)[22]. However, the data should be interpreted with caution as the medication categories were not mutually exclusive. In summary, sulfasalazine and 5-ASA are considered safe even during the COVID-19 pandemic and should be continued.

***Corticosteroids***

Corticosteroids are often used as a first-line treatment in IBD as an initial treatment to induce remission and management of acute flares. Prolonged use of steroids is associated with immunosuppression, opportunistic infections and increased mortality in IBD patients[27]. Due to these immunosuppressive and anti-inflammatory properties, systemic steroids have been evaluated in multiple randomized clinical trials and found to be promising in the management of severe and critically ill COVID-19 cases[28,29]. There is recent publication of prospective meta-analysis by World Health Organization REACT *i.e.*, Rapid Evidence Appraisal for COVID-19 Therapies. The meta-analysis included data from 7 clinical trials involving more than 1700 COVID-19 patients and concluded that corticosteroids has mortality benefits[30]. Though there is limited information on the use of steroids in COVID-positive IBD patients, the present evidence linked the concurrent steroid use to increased rates of hospitalization and severe COVID-19 infection in IBD patients[22,23].

***Immunomodulators***

Immunomodulators such as methotrexate and thiopurines (azathioprine and 6-mercaptopurine) are found to be effective as monotherapy and in combined therapy for IBD patients. Though immunomodulators are usually safe, their use has been associated with lymphopenia (which is associated with poor prognosis in COVID-19 patients) and opportunistic viral infections such as herpes simplex and viral warts[31]. *In vitro* studies suggest that thiopurines have potential antiviral activity against SARS-COV or MERS-COV, but these results were not reproduced in humans[32]. Methotrexate and thiopurines are safe and should be continued in stable IBD patients without COVID-19 infection. According to the SECURE-IBD registry data, methotrexate and thiopurines are associated with severe SARS-CoV-2 infection in 10%-11% of IBD patients. Gastroenterologists can consider discontinuing immunomodulators in IBD patients with suspected and confirmed COVID-19 infections[22].

***Biologics***

Biologics such as anti-TNF agents (infliximab, adalimumab, certolizumab and golimumab), anti-integrin (vedolizumab) and anti-interleukin-12/23 biologics (ustekinumab) are safe and effective treatment modalities for moderate-to-severe CD and UC[33]. With anti-TNF therapy, there are risks of opportunistic viral infections, reactivation of hepatitis B infection, and latent tuberculosis[34]. According to current recommendations, biologics should be continued in stable IBD patient without COVID-19 infection to prevent acute flares and immunogenicity. However, the clinician can consider holding biological therapy for 2 wk or more if an IBD patient is exposed to COVID-19 and discontinue it if patients have active COVID-19 infection until the patient clears the infection[35].

Tofacitinib, an oral JAK inhibitor, is approved for the management of UC. According to expert opinion, tofacitinib should be continued in the lowest possible dose to maintain remission. Patients on tofacitinib in contact with someone positive for COVID-19 should consider temporarily withholding the medication for two weeks. In patients with confirmed COVID-19 infection, consideration for discontinuation of tofacitinib should be made until the patient clears the infection[31].

**NON-PHARMACOLOGICAL MEASURES—PREVENTION OF COVID-19 INFECTION IN IBD PATIENTS**

Emerging data reveals that patients with IBD are not at higher risk of COVID-19 infection, and like the general population, should follow universal precautions to prevent infection. Current guidelines, expert opinion, and lessons learned from experience of epicenters such as Wuhan, China, Milan, Italy, New York City, USA and more recently Brazil, highlight the importance of patient education regarding self-prevention measures, minimizing contact with health care facilities through telemedicine, and ensuring continuation of IBD medicines to prevent COVID-19 infection and IBD flare[12,36-38].

***Health optimization and malnutrition***

Nutrition is an important determinant of health and malnutrition is established to be associated with multiple negative health outcomes in general. This is also be true in the case of COVID-19 infection[39]. Data from China and North America show that COVID-19 infections tend to be more severe (defined as the need for hospitalization, ICU admission, and ventilator use) and with higher mortality in the elderly, patients with underlying health conditions, and the malnourished[40]. Older age and co-morbid conditions are independently associated with sarcopenia (reduced muscle mass) and hypoalbuminemia. Patients with IBD are often malnourished due to their symptoms and medications such as steroids, sulfasalazine and methotrexate[41]. Optimization of nutritional status can prevent severe COVID-19 infection. IBD patients should continue with mineral and vitamin supplementation and to avoid smoking and foods that can trigger flares[42].

***Minimize risk of COVID-19 infection***

So far, the best preventive strategy to avoid COVID-19 is by minimizing the risk of exposure to the virus. This can be achieved by following universal precautions and avoiding contact with healthcare facilities.

***Reduce the risk of transmission***

All IBD patients must be educated about preventive strategies to mitigate the COVID-19 pandemic. According to the WHO guidelines, the general population including patients with IBD should clean their hands with an alcohol-based hand sanitizer or wash with soap and water regularly and thoroughly, maintain social distance of at least 3 feet, avoid going to crowded spaces, public toilets, touching the face/eyes/nose/mouth, cancel non-essential travel, follow good respiratory hygiene (*i.e.*, cover sneeze and cough), and seek appropriate medical attention if symptoms develop suggestive of SARS-CoV-2 infection[43,44].

***Immunization***

IBD patients are at risk of vaccine-preventable viral and bacterial infections. They should be encouraged to receive pneumococcal (PCV13 and PPSV 23) and influenza vaccines to prevent co-infections[12].

***Avoid exposure to health care facilities-Role of telemedicine services***

To prevent spread of the COVID-19 infection, IBD patients and physicians are encouraged to use telemedicine to avoid unnecessary exposure to COVID-19. Telemedicine is defined by the Institute of Medicine as the use of electronic and telecommunications technology to provide and support healthcare when distance separates the participants[45]. Prior to COVID-19, the utilization of telemedicine in North America was limited due to several reasons which included low reimbursements from insurance companies, lack of training, unavailability of the equipment, software constraints, and other technical issues[46]. Telemedicine services are found to be useful for patient monitoring, advice, and education during this unprecedented time and has been adopted by health systems globally[47,48]. Similarly, in the United States the use of telemedicine services is tremendously expanded due to improved reimbursements from insurance companies and Centers for Medicare and Medicaid Services.

***Prevention of COVID-19 at infusion center****s*

To prevent the risk of flares and immunogenicity, IBD patients should continue with their infusions at scheduled times. However, patients and infusion center management should take measures to reduce the risk of coronavirus transmission. Examples of these measures include implementation of pre-admission screening protocols to assess for the symptoms of SARS-CoV-2 infection, preferably 1-2 d before the scheduled infusions. On the day of infusion, patients should use designated entry points to avoid contact with hospitalized patients[49]. No accompanying persons should be allowed in the infusion center. Patients with IBD should be re-screened for COVID-19 symptoms with temperature measurement on the day of infusion. All patients and staff should wear surgical masks with rearrangement of seats approximately 1.5 m apart[50].

**ENDOSCOPY IN IBD PATIENTS DURING THE PANDEMIC**

Due to the risk of community transmission from infected aerosols and potential fecal shedding of the SARS-CoV-2, endoscopies should be scheduled in carefully selected patients after weighing the risks and benefits. Currently, only urgent and emergent endoscopic procedures are recommended by the British Society of Gastroenterology (BSG), the IOIBD, the ECCO, and the CCFA to avoid potential exposure of SARS-CoV-2 to health care personnel and patients[23,35,51] (Figure 1). However, it is not clear when to consider endoscopy as urgent or emergent in patients with IBD. Iacucci *et al*[52] published a review articles in *Lancet Gastroenterology and Hepatology* to discuss four different scenarios that could justify the need for endoscopic evaluation (diagnostic and therapeutic) during the pandemic. In the first scenario, the authors discussed a case of a suspected new diagnosis of IBD with possible moderate-to-high degree of inflammation as evident by elevated inflammatory markers and fecal calprotectin. In this particular scenario, flexible sigmoidoscopy or colonoscopy with random biopsies were recommended before initiating biologics. Other indications for urgent endoscopy for IBD patients include acute flare of UC, especially if the last endoscopic procedure was more than 3 mo ago, partial bowel obstruction in patients with IBD needing urgent endoscopic decompression or stent placement, and ascending cholangitis or worsening jaundice in patient with primary sclerosing cholangitis and IBD requiring endoscopic retrograde cholangiopancreatography with stent placement[52].

All IBD patients needing endoscopic procedures should be tested for COVID-19. Suspected and confirmed cases should be performed in a negative-pressure room and health care providers should follow standardized precautions including hand hygiene and use of disposable gowns, N95 mask with surgical mask, gloves, and head and shoe covers. In addition, the American and European gastrointestinal societies (ASGE and ESGE) published guidelines for infection control and scope reprocessing during the COVID-19 pandemic. After procedures, the endoscope should be placed in a fully enclosed and labeled container for transportation to the decontamination room. The reprocessing staff should also wear adequate personal protective equipment (PPE) to limit their exposure. Commonly used disinfectant (bactericidal, mycobactericidal, fungicidal and viricidal) can be used to clean scopes after procedures and no special handling instruction are recommended. Meticulous attention should be paid to clean the procedure room after each procedure and at the end of the day[53-55].

**SURGICAL MANAGEMENT OF PATIENTS WITH IBD DURING THE COVID-19 PANDEMIC**

Over the past decade, significant advances have been made in the medical management of IBD. However, timely surgery remains a vital part in the current multi-modal approach to manage both CD and UC and their complications. According to the estimates about half the patients with UC and up to two-third of people with CD will eventually require surgery[56]. Surgery in IBD patients can be performed electively, *e.g.* to eliminate risk of cancer and management of medical refractory IBD, or emergently, such as in cases of intestinal perforation, toxic megacolon, strictures, fistulas and abscesses[57].

Surgical management of IBD poses unique challenge during the current pandemic, especially the timing of the surgery. Poor outcomes after elective surgery in COVID-19 patients were reported in the study published by Lei *et al*[58]. In this retrospective analysis, 34 patients who underwent unintentional elective surgeries during the incubation period of COVID-19 were included. All patients developed pneumonia from SARS-CoV-2 infection shortly after their procedure, approximately 44% of patients needed ICU admission, and 20.5% of patients died from complications such as adult respiratory distress syndromes, arrythmias and cardiac arrest. Patients with active IBD or in remission are susceptible to COVID-19 and the possibility of increased post-operative morbidity and mortality is an important factor to consider for scheduling non-emergent and elective procedures. In addition, there is always a risk of staff exposure from suspected or confirmed COVID-19 patients during the peri-operative period and nosocomial transmission to other patients[59]. Therefore, the CCFA, ECCO, IOIBD, and BSG recommend reducing contact in the healthcare settings by delaying elective non-essential endoscopies and surgical procedures to reduce possible exposure to SARS-CoV-2 infection and to conserve scarce resources in this time of uncertainty[23,35,51]. However, delays in IBD surgeries caused by COVID-19 pandemic can exert tremendous pressure on an already strained healthcare system, harm to IBD patients, and causes anxiety for patients and families.

In April 2020, the IOIBD and American Society of Colon and Rectal Surgeons developed expert-based recommendations for the surgical management of IBD patients during the COVID-19 pandemic. According to the recommendations, the peri-operative considerations includes testing all IBD patients requiring surgery for SARS-CoV-2 preoperatively due to the high risk of transmission from asymptomatic and pre-symptomatic COVID-19 infected patients and carriers. In addition, the experts recommend practicing universal precautions peri-operatively due to questionable reliability of the test, wide variations in the sensitivity and specificity resulting in high false positives and shedding of virus through aerosol and fecal-oral route in asymptomatic and pre-symptomatic patients. To prevent nosocomial transmission, all staff should wear PPE such as N95 masks covered by surgical masks and plastic face shields. The surgeries should be performed in negative-pressure rooms on suspected and confirmed COVID-19 patients with IBD[60] (Figure 2).

**RECOMMENDATIONS FOR SURGICAL MANAGEMENT OF CD**

Patients with CD often need operative interventions to alleviate symptoms of severe inflammation in the intestine, treat complications such as intestinal hemorrhage, perforation, abscess formation, fistulas, strictures and to improve quality of life. Per experts’ recommendations, indications for emergent surgical interventions in patient with CD during the COVID-19 pandemic includes medically unstable patient with active intestinal hemorrhage not amenable to or failure to controlled by angiography, acute small bowel obstruction, perforation, peritonitis or abscess not responding to percutaneous drainage and antibiotics. Small bowel obstruction and contained perforation in otherwise stable patients can be managed non-operatively and surgery is reserved for people who fail to respond conservative treatment. Invasive small bowel and colon cancer should be discussed in tumor board and scheduled for procedure promptly. Cases of medically refractory CD, chronic small bowel obstruction due to strictures, and intra-abdominal fistula should be discussed in multi-disciplinary team meetings and should prioritize these patients once surgical slots become available. Regarding perianal CD patient with active perianal abscess, intractable pain, and sepsis not responding to minimally invasive surgical methods and broad-spectrum antibiotics should also be scheduled for fecal diversion surgery urgently.

**RECOMMENDATIONS FOR SURGICAL MANAGEMENT OF UC**

Medical refractory disease and complications of severe UC such as intestinal hemorrhage, perforation and toxic megacolon are indications for emergent laparotomy and surgery should not be delayed. Invasive colorectal cancer with and without metastatic disease should be discussed in multi-disciplinary tumor board meetings and should be treated promptly. Surgeries for patients with UC with low-grade to high-grade dysplasia may be delayed in the short term and surgeons should maintain records of the deferred procedures to schedule them once slots are available[61].

**IBD PATIENTS IN THE CLINICAL TRIALS**

The purpose of the IBD clinical trial is to find the most effective and safest treatment. Currently there are several IBD clinical trials are in process globally and hundreds of patients enrolled in them. The COVID-19 pandemic has made overall negative impacts on clinical trials due to disruptions, social distancing policies, travel limitations and delays in the supply of investigational medications. According to the CCFA, IBD patients currently enrolled in clinical trials should contact clinical research staff for updates regarding any changes to trials through emails or phone calls and try to delay the follow up visits and arrange for home drug delivery.

**GUIDELINE TO MANAGING PREGNANT IBD PATIENTS DURING THE PANDEMIC**

In non-pandemic times, the management of IBD can be broken down into three phases: pre-conception, pregnancy period, and post-partum. Prior to conception, IBD care should focus on disease and medication management with the goals to maintain the patient in remission and maintaining medications that are safe in the event a patient becomes pregnant[62]. Medications for IBD are thought to be safe in pregnancy with the exception of methotrexate and thalidomide which are category X[64]. If a patient is on methotrexate, the medication must be stopped at least 3 mo in advance before conception, while biologics and thiopurines are lower risk and can be continued during pregnancy. During pregnancy, patients should follow closely with their gastroenterologist and have monitoring for symptoms every two weeks. If there is a concern of a flare, diagnostic work-up includes labs, imaging, and endoscopy studies or surgery if severely toxic. Medication management is similar to non-pregnant women with the exception of usage of methotrexate, tofacitinib, and thiopurine usage in thiopurine-naïve patients[62].

During these pandemic times, there have been reports of vertical transmission of COVID-19 from an infected mother to the newborn and neonates with COVID-19 have had a range of outcomes[65,66]. Currently, there are no studies that have focused on the outcomes of pregnant women with IBD who have become infected with COVID-19 regarding IBD activity, pregnancy course, and neonatal health. The CCFA recommends continuing current IBD management with no changes in the setting of the pandemic and to work closely with gastroenterologists. Rosen *et al*[66] reviewed the management of acute severe UC in pregnant women with SARS-CoV-2. They describe a case of young woman who tested positive for COVID-19 with an UC flare and respiratory symptoms that was managed with intravenous cyclosporin 2 mg/kg since she was unable to transition to oral prednisone and azithromycin and hydroxychloroquine. Unfortunately, she had a spontaneous abortion during her hospital course[67]. There is no known optimal management of IBD pregnant women in this pandemic, but given current recommendations, the usage of biologics or cyclosporin may be used for salvage therapy while restricting steroid usage.

**MENTAL HEALTH MANAGEMENT IN IBD PATIENTS DURING THE COVID-19 PANDEMIC**

The mental health and stress from the outbreak of COVID-19 can affect people of all ages. In those living with IBD, the severity of medical disease can greatly affect their mental health with the added stress of the COVID-19 pandemic. The CDC has recommended a range of therapies to cope with the stress of the pandemic including taking breaks from news stories, taking care of the body with breathing exercises, stretching, healthy eating habits, regular exercise, good sleep hygiene, and to avoid substances such as alcohol and drugs. They also recommend making time to unwind and to take time to connect with others[68]. In Italy, Sani *et al*[68] described that with protracted social isolation there will be concerns of increase of disorders such as anxiety, mood, additive and thought disorders in patients of mental health during and after the COVID-19 pandemic. Furthermore, the authors recommended active ongoing participation of mental health professionals during this critical period[69].

In IBD patients, there are no specific guidelines on the optimal management of mental health. However, the CCFA recommend the same guidelines as the CDC with turning off media and news updates, setting a schedule, regular stress management, connecting with family and friends, enforcing a daily routine, and making use of meeting with mental health professionals[70]. Additionally, patients with IBD should find support groups either locally or through online resources.

**MANAGEMENT OF IBD PATIENTS WITH COVID-19**

Recommendations for the management of IBD patients without concern for active COVID-19 infection have been to maintain medications if IBD disease activity is stable[72]. Additionally, patients should maintain these medications to avoid relapse and its consequences[35]. However, it is unclear the appropriate management of SARS-CoV-2 positive IBD patients. Management of these patients can be divided into those with stable IBD disease or acute flares and further divided to patients with COVID-19 that are asymptomatic and symptomatic (Figure 3). Regardless of COVID-19 positivity, patients should adhere to strict social distancing per their local recommendations.

***Quiescent IBD patient with active COVID-19***

Since rapid testing has been increasing, patients with no or minimal symptoms may test positive for COVID-19. An expert commentary by Rubin *et al*[23] with the support of IOIBD stated that asymptomatic COVID-19-positive IBD patients should have their medications regimens changed to monitor for the development of symptoms. Specifically, monoclonal antibody therapies such as anti-TNF, ustekinumab, or vedolizumab hold for 14 days with monitoring of COVID-19 symptoms and recommend reinitiating therapy after two weeks if these symptoms do not develop. Immunomodulators such as thiopurines, methotrexate, and tofacitinib should be held. However, stopping 5-aminosalicylates in patient who tested positive was felt to be inappropriate on the most recent survey by the IOIBD[23].

The IOIBD has different recommendations for IBD patients who develop COVID-19. First off, survey participants of the IOIBD felt that it was inappropriate to hold 5-aminosalicylates and therefore were considered safe to continue. Monoclonal antibody therapy (such as anti-TNF and ustekinumab), immunomodulators (thiopurines, methotrexate, and tofacitinib), and corticosteroids (prednisone greater than 20 mg per day) should be discontinued. It is uncertain whether vedolizumab or non-systemic corticosteroids (such as budesonide) should be held in setting of COVID-19[23]. There is no consensus on the timing of recommencement once infection occurred, but one recommendation by Al-Ani *et al*[12] stated to reinitiate IBD therapy once infection is cleared defined by two negative nasopharyngeal swabs 24 h apart at least 8 d after symptoms or waiting at least 14 d after symptom onset and clinical improvement with resolution of fever for at least three days.

***Acute flare with active COVID-19***

Exacerbations of IBD have been rare, less than 10 percent, during the pandemic; however, patients who develop flares may requiring endoscopic evaluation[72]. Given the concern of fecal-oral transmission with the detection of COVID-19 in stool specimens, there is a risk of transmission from patient to health-care provider[73,74]. Therefore, it is critical to ensure patients be tested or screened for COVID-19 prior to considering endoscopic evaluation or therapy.

In patients suspicious for flares, *i.e.* those with new abdominal pain, diarrhea, and fever, and COVID-19, treatment and evaluation should focus on evaluating gastroenterology symptoms which include ruling out enteric infections and confirming inflammation (with inflammatory markers such as fecal calprotectin or cross-sectional imaging like CT or MR enterography). To note, COVID-19 can illicit an inflammatory response on the gut therefore elevated of fecal calprotectin must be cautiously used to diagnose a flare and a threshold of < 100 mg/g should be used to rule out active inflammation[74]. If confirmed relapse, treatment focuses on severity of flare and COVID-19. For mild COVID symptoms, flares should be treated as done as per usual. In more severe COVID symptoms, the risk-benefits must be weighed on starting IBD therapies, increasing therapy, or holding IBD therapy[35]. Steroids, specifically prednisone, should be decreased to the lowest possible dose (less than 20 mg per day) in non-severe cases as they are found to be associated with poor outcomes in SECURE IBD study and by expert opinion by Japan IBD COVID-19 task force[75,76]. However, patient with severe and progressive COVID-19 infection with requirement of mechanical ventilation current recommendations are to continue with IV steroids[30]. There is limited evidence of medications on COVID-19 and the risk of infection. The BSG reported that IBD medications including all classes of immunomodulators and biologics are safe with no added risk of SARS-CoV-2 infection[77]. However, with medications being trialed for the treatment of COVID-19, caution should be advised in IBD patients to avoid drug-drug interactions[12].

A well-known anti-malarial drug and treatment for rheumatoid arthritis and lupus that was used in the early stages of the pandemic was hydroxychloroquine/chloroquine. This is an immunomodulator against cytokines that has interactions with other immunomodulators, such as methotrexate, azathioprine, and tofacinib. Concurrent chloroquine usage with thiopurines or methotrexate can have an increased risk of myelosuppression; therefore, it is recommended to stop thiopurines and methotrexate in the event of chloroquine usage. Furthermore, chloroquine may increase tofacitinib levels; however, the clinically significant of this is unknown[12]. Overall, hydroxychloroquine/chloroquine has quickly fallen out of favor given the cardiac complications[78].

Remdesivir, a nucleoside prodrug, has antiviral properties a broad spectrum of viruses[79]. There has been no medication reported with concurrent usage of remdesivir with corticosteroids, thiopurines, methotrexate, tofacitinib, biologics or 5-ASA[12].

Kaletra (Lopinavir/Ritonvair) is a protease inhibitor used for the treatment of human immunodeficiency virus. A randomized controlled open label trial involving a total of one hundred and ninety-nine patients with SARS-CoV-2 underwent randomization and ninety-nine patients received lopinavir-ritonavir. Results of the trial showed no benefits of lopinavir-ritonavir as compared to standard care[80]. However, interactions have been documented with steroids and tofacitinib, causing increased levels of both latter drugs. Furthermore, tofacitinib should be stopped if necessary. No interactions were noted with thiopurines, methotrexate, 5-ASA, or biologics[12].

**POST COVID-19 INFECTION CARE IN IBD PATIENT**

While the COVID-19 pandemic continues to evolve, there is speculation on care in the post-pandemic period. As stated earlier, IBD therapy resumption is thought to be safe once the COVID infection is cleared, defined by negative testing over an 8-d period or improving symptoms after 14 day of symptom onset without repeat COVID testing[12] and/or after 2 nasopharyngeal PCR tests are negative. However, for post-infection endoscopy, there are numerous barriers including the concern of fecal-oral transmission, prevention of outbreaks, and finally the waitlist from cancelled procedures[52,73]. Recommendations from experts including Iacucci *et al*[52]suggest prioritizing patients according to symptoms, lab testing, medications, surgical history, and cancer risk.

**CONCLUSION**

Management of IBD is unique and challenging especially during this unprecedented time. There is always a concern of increased risk of SARS-CoV-2 among IBD patients due to nature of the disease and use of immunosuppressive medications. However, it is clear from current guidelines and expert opinion that the risk of SARS-CoV-2 infection in IBD patients is similar to that of the general population. Hence, those with IBD should continue immunomodulators and immunosuppressive agents except corticosteroids to prevent risk of flare and development of immunogenicity. Data from epicenters such as Milan and New York City, as well as the SECURE-IBD registry, show that older age, active IBD, co-morbid conditions and use of steroids are associated with risk of severe COVID-19 infection among IBD patients. Similarly, predictors of poor outcome of COVID-19 infection have been well documented in immunocompromised patients in the general population. Considering the current literature, gastroenterologists should focus on educating their IBD patients for measures to prevent infection such as universal precautions, use of telemedicine and deferring non-elective surgical and endoscopic procedures.

**REFERENCES**

1 **Wang C**, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet* 2020; **395**: 470-473 [PMID: 31986257 DOI: 10.1016/S0140-6736(20)30185-9]

2 **Habibzadeh P**, Stoneman EK. The Novel Coronavirus: A Bird's Eye View. *Int J Occup Environ Med* 2020; **11**: 65-71 [PMID: 32020915 DOI: 10.15171/ijoem.2020.1921]

3 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

4 **Wang C**, Liu Z, Chen Z, Huang X, Xu M, He T, Zhang Z. The establishment of reference sequence for SARS-CoV-2 and variation analysis. *J Med Virol* 2020; **92**: 667-674 [PMID: 32167180 DOI: 10.1002/jmv.25762]

5 **World Health Organization**. Coronavirus disease (COVID-19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjw\_Y\_8BRBiEiwA5MCBJsaxT8pZZelNJ9e8wYH4Spl-LWecrtNO0F2kKYOCOMrhuyT5UOIhZRoCskMQAvD\_BwE

6 **Centers for Disease Control and Prevention**. Coronavirus Disease 2019 (COVID-19). Available from: https://www.cdc.gov/coronavirus/2019-ncov/index.html

7 **Yao Q**, Wang P, Wang X, Qie G, Meng M, Tong X, Bai X, Ding M, Liu W, Liu K, Chu Y. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. *Pol Arch Intern Med* 2020; **130**: 390-399 [PMID: 32329978 DOI: 10.20452/pamw.15312]

8 **Podolsky DK**. Inflammatory bowel disease. *N Engl J Med* 2002; **347**: 417-429 [PMID: 12167685 DOI: 10.1056/NEJMra020831]

9 **Song Y**, Liu P, Shi XL, Chu YL, Zhang J, Xia J, Gao XZ, Qu T, Wang MY. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. *Gut* 2020; **69**: 1143-1144 [PMID: 32139552 DOI: 10.1136/gutjnl-2020-320891]

10 **Ng SC**, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. *Lancet* 2018; **390**: 2769-2778 [PMID: 29050646 DOI: 10.1016/S0140-6736(17)32448-0]

11 **Bonovas S**, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clin Gastroenterol Hepatol* 2016; **14**: 1385-1397.e10 [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039]

12 **Al-Ani AH**, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. *Aliment Pharmacol Ther* 2020; **52**: 54-72 [PMID: 32348598 DOI: 10.1111/apt.15779]

13 **Han C**, Duan C, Zhang S, Spiegel B, Shi H, Wang W, Zhang L, Lin R, Liu J, Ding Z, Hou X. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. *Am J Gastroenterol* 2020; **115**: 916-923 [PMID: 32301761 DOI: 10.14309/ajg.0000000000000664]

14 **Redd WD**, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC, Shen L, Chan WW. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. *Gastroenterology* 2020; **159**: 765-767.e2 [PMID: 32333911 DOI: 10.1053/j.gastro.2020.04.045]

15 **Nobel YR**, Phipps M, Zucker J, Lebwohl B, Wang TC, Sobieszczyk ME, Freedberg DE. Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States. *Gastroenterology* 2020; **159**: 373-375.e2 [PMID: 32294477 DOI: 10.1053/j.gastro.2020.04.017]

16 **Pan L**, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *Am J Gastroenterol* 2020; **115**: 766-773 [PMID: 32287140 DOI: 10.14309/ajg.0000000000000620]

17 **Ling Y**, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)* 2020; **133**: 1039-1043 [PMID: 32118639 DOI: 10.1097/CM9.0000000000000774]

18 **Carvalho A,** Alqusairi R, Adams A, Paul M, Kothari N, Peters S, DeBenedet AT. SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease. *Am J Gastroenterol* 2020; **115**: 942-946 [PMID: 32496741 DOI: 10.14309/ajg.0000000000000667]

19 **D'Amico F**, Danese S, Peyrin-Biroulet L. Systematic Review on IBD Patients With COVID-19: It Is Time to Take Stock. *Clin Gastroenterol Hepatol* 2020 [PMID: 32777550 DOI: 10.1016/j.cgh.2020.08.003]

20 **An P,** Ji M, Ren H, Su J, Kang J, Yin A, Zhou Q, Shen L, Zhao L, Jiang X, Xiao Y, Tan W, Lv X, Li J, Liu S, Zhou J, Chen H, Xu Y, Liu J, Chen M, Cao J, Zhou Z, Shen L, Tan S, yu H, Dong W, Ding Y. Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China. *SSRN J* 2020 [DOI: 10.2139/ssrn.3543590]

21 **Bezzio C**, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, Casini V, Ricci C, Zingone F, Amato A, Caprioli F, Lenti MV, Viganò C, Ascolani M, Bossa F, Castiglione F, Cortelezzi C, Grossi L, Milla M, Morganti D, Pastorelli L, Ribaldone DG, Sartini A, Soriano A, Manes G, Danese S, Fantini MC, Armuzzi A, Daperno M, Fiorino G; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. *Gut* 2020; **69**: 1213-1217 [PMID: 32354990 DOI: 10.1136/gutjnl-2020-321411]

22 **Brenner EJ,** Ungaro RC, Colombel JF, Kappelman MD. SECURE-IBD Database Public Data Update. Available from: https://covidibd.org/

23 **Rubin DT**, Abreu MT, Rai V, Siegel CA; International Organization for the Study of Inflammatory Bowel Disease. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. *Gastroenterology* 2020; **159**: 6-13.e6 [PMID: 32272113 DOI: 10.1053/j.gastro.2020.04.002]

24 **Danese S**, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. *Nat Rev Gastroenterol Hepatol* 2020; **17**: 253-255 [PMID: 32214232 DOI: 10.1038/s41575-020-0294-8]

25 **Crohn's and Colitis Foundation**. COVID-19 (Coronavirus): What IBD Patients Should Know. Available from: https://www.crohnscolitisfoundation.org/coronavirus/what-ibd-patients-should-know

26 **Wang Y**, Parker CE, Bhanji T, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2016; **4**: CD000543 [PMID: 27101467 DOI: 10.1002/14651858.CD000543.pub4]

27 **Sairenji T**, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. *Prim Care* 2017; **44**: 673-692 [PMID: 29132528 DOI: 10.1016/j.pop.2017.07.010]

28 **Dequin PF**, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, François B, Aubron C, Ricard JD, Ehrmann S, Jouan Y, Guillon A, Leclerc M, Coffre C, Bourgoin H, Lengellé C, Caille-Fénérol C, Tavernier E, Zohar S, Giraudeau B, Annane D, Le Gouge A; CAPE COVID Trial Group and the CRICS-TriGGERSep Network. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* 2020; **324**: 1-9 [PMID: 32876689 DOI: 10.1001/jama.2020.16761]

29 **RECOVERY Collaborative Group**, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020 [PMID: 32678530 DOI: 10.1056/NEJMoa2021436]

30 **WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group**, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020; **324**: 1-13 [PMID: 32876694 DOI: 10.1001/jama.2020.17023]

31 **Pithadia AB**, Jain S. Treatment of inflammatory bowel disease (IBD). *Pharmacol Rep* 2011; **63**: 629-642 [PMID: 21857074 DOI: 10.1016/s1734-1140(11)70575-8]

32 **Cheng KW**, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, Sun CY, Chou CY. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. *Antiviral Res* 2015; **115**: 9-16 [PMID: 25542975 DOI: 10.1016/j.antiviral.2014.12.011]

33 **Gutin LS**, Lam AY, Velayos FS, Santos SA. Going Viral: Management of IBD in the Era of the COVID-19 Pandemic. *Dig Dis Sci* 2020; **65**: 1571-1575 [PMID: 32363528 DOI: 10.1007/s10620-020-06299-y]

34 **Murdaca G**, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Infection risk associated with anti-TNF-α agents: a review. *Expert Opin Drug Saf* 2015; **14**: 571-582 [PMID: 25630559 DOI: 10.1517/14740338.2015.1009036]

35 **Rubin DT**, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. *Gastroenterology* 2020; **159**: 350-357 [PMID: 32283100 DOI: 10.1053/j.gastro.2020.04.012]

36 **Higgins PDR**, Ng S, Danese S, Rao K. The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients. *Crohns Colitis 360* 2020; **2**: otaa026 [PMID: 32377636 DOI: 10.1093/crocol/otaa026]

37 **Queiroz NSF**, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. *Clinics (Sao Paulo)* 2020; **75**: e1909 [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909]

38 **Fiorino G**, Allocca M, Furfaro F, Gilardi D, Zilli A, Radice S, Spinelli A, Danese S. Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. *J Crohns Colitis* 2020; **14**: 1330-1333 [PMID: 32211765 DOI: 10.1093/ecco-jcc/jjaa058]

39 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

40 **Hernández Benabe S**, Langshaw AH. IBD in the Times of COVID-19. *Inflamm Bowel Dis* 2020; **26**: e92 [PMID: 32448895 DOI: 10.1093/ibd/izaa132]

41 **Martínez Gómez MJ**, Melián Fernández C, Romeo Donlo M. Nutrition in inflammatory bowel disease *Nutr Hosp* 2016; **33**: 348 [PMID: 27571867 DOI: 10.20960/nh.348]

42 **Laviano A**, Koverech A, Zanetti M. Nutrition support in the time of SARS-CoV-2 (COVID-19). *Nutrition* 2020; **74**: 110834 [PMID: 32276799 DOI: 10.1016/j.nut.2020.110834]

43 **Ahmed F**, Zviedrite N, Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review. *BMC Public Health* 2018; **18**: 518 [PMID: 29669545 DOI: 10.1186/s12889-018-5446-1]

44 **Fong MW**, Gao H, Wong JY, Xiao J, Shiu EYC, Ryu S, Cowling BJ. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-Social Distancing Measures. *Emerg Infect Dis* 2020; **26**: 976-984 [PMID: 32027585 DOI: 10.3201/eid2605.190995]

45 **Institute of Medicine (US) Committee on Evaluating Clinical Applications of Telemedicine**, Field MJ, Editors. Telemedicine: A Guide to Assessing Telecommunications in Health Care. Washington: National Academies Press, 1996 [PMID: 20845554 DOI: 10.17226/5296]

46 **Scott Kruse C**, Karem P, Shifflett K, Vegi L, Ravi K, Brooks M. Evaluating barriers to adopting telemedicine worldwide: A systematic review. *J Telemed Telecare* 2018; **24**: 4-12 [PMID: 29320966 DOI: 10.1177/1357633X16674087]

47 **Berg EA**, Picoraro JA, Miller SD, Srinath A, Franciosi JP, Hayes CE, Farrell PR, Cole CR, LeLeiko NS. COVID-19-A Guide to Rapid Implementation of Telehealth Services: A Playbook for the Pediatric Gastroenterologist. *J Pediatr Gastroenterol Nutr* 2020; **70**: 734-740 [PMID: 32443021 DOI: 10.1097/MPG.0000000000002749]

48 **Hollander JE**, Carr BG. Virtually Perfect? Telemedicine for Covid-19. *N Engl J Med* 2020; **382**: 1679-1681 [PMID: 32160451 DOI: 10.1056/NEJMp2003539]

49 **Magro F**, Abreu C, Rahier JF. The daily impact of COVID-19 in gastroenterology. *United European Gastroenterol J* 2020; **8**: 520-527 [PMID: 32281517 DOI: 10.1177/2050640620920157]

50 **Allocca M**, Fiorino G, Furfaro F, Gilardi D, Radice S, D'Amico F, Zilli A, Danese S. Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. *Clin Gastroenterol Hepatol* 2020; **18**: 1882-1883 [PMID: 32304737 DOI: 10.1016/j.cgh.2020.04.028]

51 **Lamb CA**, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H; IBD guidelines eDelphi consensus group, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019; **68**: s1-s106 [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484]

52 **Iacucci M**, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. *Lancet Gastroenterol Hepatol* 2020; **5**: 598-606 [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9]

53 **ASGE Quality Assurance in Endoscopy Committee**, Calderwood AH, Day LW, Muthusamy VR, Collins J, Hambrick RD 3rd, Brock AS, Guda NM, Buscaglia JM, Petersen BT, Buttar NS, Khanna LG, Kushnir VM, Repaka A, Villa NA, Eisen GM. ASGE guideline for infection control during GI endoscopy. *Gastrointest Endosc* 2018; **87**: 1167-1179 [PMID: 29573782 DOI: 10.1016/j.gie.2017.12.009]

54 **Beilenhoff U**, Biering H, Blum R, Brljak J, Cimbro M, Dumonceau JM, Hassan C, Jung M, Kampf B, Neumann C, Pietsch M, Pineau L, Ponchon T, Rejchrt S, Rey JF, Schmidt V, Tillett J, van Hooft JE. Reprocessing of flexible endoscopes and endoscopic accessories used in gastrointestinal endoscopy: Position Statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology Nurses and Associates (ESGENA) - Update 2018. *Endoscopy* 2018; **50**: 1205-1234 [PMID: 30458567 DOI: 10.1055/a-0759-1629]

55 **Neumann H**, Emura F, Bokemeyer B, Guda N, Tajiri H, Matsumoto T, Rubin DT. Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. *Dig Endosc* 2020 [PMID: 32369646 DOI: 10.1111/den.13712]

56 **Meregaglia M**, Banks H, Fattore G. Hospital Burden and Gastrointestinal Surgery in Inflammatory Bowel Disease Patients in Italy: A Retrospective Observational Study. *J Crohns Colitis* 2015; **9**: 853-862 [PMID: 26069194 DOI: 10.1093/ecco-jcc/jjv104]

57 **Trier Moller F**, Andersen V, Andersson M, Jess T. Hospital Admissions, Biological Therapy, and Surgery in Familial and Sporadic Cases of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011. *Inflamm Bowel Dis* 2015; **21**: 2825-2832 [PMID: 26288000 DOI: 10.1097/MIB.0000000000000545]

58 **Lei S**, Jiang F, Su W, Chen C, Chen J, Mei W, Zhan LY, Jia Y, Zhang L, Liu D, Xia ZY, Xia Z. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *EClinicalMedicine* 2020; **21**: 100331 [PMID: 32292899 DOI: 10.1016/j.eclinm.2020.100331]

59 **D'Amico F**, Peyrin-Biroulet L, Danese S. Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. *Gastroenterology* 2020; **158**: 2302-2304 [PMID: 32305331 DOI: 10.1053/j.gastro.2020.04.032]

60 **Remzi FH**, Panis Y, Spinelli A, Kotze PG, Mantzaris G, Söderholm JD, d'Hoore A, Bemelman WA, Yamamoto T, Pemberton JH, Tiret E, Øresland T, Fleshner P. International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic. *Dis Colon Rectum* 2020; **63**: 870-873 [PMID: 32355056 DOI: 10.1097/DCR.0000000000001718]

61 **Crohn's and Colitis Foundation**. COVID-19 & IBD: Clinical Trials. Available from: https://www.crohnscolitisfoundation.org/coronavirus/ibd-clinical-trials

62 **Mahadevan U**, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. *Am J Obstet Gynecol* 2019; **220**: 308-323 [PMID: 30948039 DOI: 10.1016/j.ajog.2019.02.027]

63 **Hashash JG**, Kane S. Pregnancy and Inflammatory Bowel Disease. *Gastroenterol Hepatol (N Y)* 2015; **11**: 96-102 [PMID: 27099578]

64 **Dong L**, Tian J, He S, Zhu C, Wang J, Liu C, Yang J. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA* 2020; **323**: 1846-1848 [PMID: 32215581 DOI: 10.1001/jama.2020.4621]

65 **Zeng L**, Xia S, Yuan W, Yan K, Xiao F, Shao J, Zhou W. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr* 2020; **174**: 722-725 [PMID: 32215598 DOI: 10.1001/jamapediatrics.2020.0878]

66 **Rosen MH**, Axelrad J, Hudesman D, Rubin DT, Chang S. Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. *Inflamm Bowel Dis* 2020; **26**: 971-973 [PMID: 32393973 DOI: 10.1093/ibd/izaa109]

67 **Centers for Disease Control and Prevention**. Coronavirus Disease 2019 (COVID-19). Available from: https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/managing-stress-anxiety.html

68 **Sani G**, Janiri D, Di Nicola M, Janiri L, Ferretti S, Chieffo D. Mental health during and after the COVID-19 emergency in Italy. *Psychiatry Clin Neurosci* 2020; **74**: 372 [PMID: 32248608 DOI: 10.1111/pcn.13004]

69 **Crohn's and Colitis Foundation**. COVID-19 & Mental Health (21 May 2020). Available from: https://www.crohnscolitisfoundation.org/coronavirus/mental-health

70 **Mao R**, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, Wu KC, Chen MH; Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Implications of COVID-19 for patients with pre-existing digestive diseases. *Lancet Gastroenterol Hepatol* 2020; **5**: 425-427 [PMID: 32171057 DOI: 10.1016/S2468-1253(20)30076-5]

71 **Bai X**, Yang H, Qian J. COVID-19 Outbreak and Inflammatory Bowel Disease Management: A Questionnaire Survey From Realistic Practice. *J Crohns Colitis* 2020; **14**: 1494-1495 [PMID: 32221526 DOI: 10.1093/ecco-jcc/jjaa064]

72 **Gu J**, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. *Gastroenterology* 2020; **158**: 1518-1519 [PMID: 32142785 DOI: 10.1053/j.gastro.2020.02.054]

73 **Pasha SB**, Fatima H, Ghouri YA. Management of inflammatory bowel diseases in the wake of COVID-19 pandemic. *J Gastroenterol Hepatol* 2020; **35**: 1449-1450 [PMID: 32246874 DOI: 10.1111/jgh.15056]

74 **Mago S**, Vaziri H, Tadros M. The utility of fecal calprotectin in the era of COVID-19 pandemic. *Gastroenterology* 2020 [PMID: 32425230 DOI: 10.1053/j.gastro.2020.05.045]

75 **Nakase H**, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Wagatsuma K, Yokoyama Y, Hisamatsu T. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. *Digestion* 2020: 1-9 [PMID: 32892197 DOI: 10.1159/000510502]

76 **Brenner EJ**, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology* 2020; **159**: 481-491.e3 [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032]

77 **Kennedy NA**, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ, Cooney R, Dart RJ, Edwards C, Fraser A, Gaya DR, Ghosh S, Greveson K, Hansen R, Hart A, Hawthorne AB, Hayee B, Limdi JK, Murray CD, Parkes GC, Parkes M, Patel K, Pollok RC, Powell N, Probert CS, Raine T, Sebastian S, Selinger C, Smith PJ, Stansfield C, Younge L, Lindsay JO, Irving PM, Lees CW. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. *Gut* 2020; **69**: 984-990 [PMID: 32303607 DOI: 10.1136/gutjnl-2020-321244]

78 **U.S. Food and Drug Administration**. 2020. FDA Cautions Use OF Hydroxychloroquine/Chloroquine For COVID-19. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or

79 **Wang Y**, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569-1578 [PMID: 32423584 DOI: 10.1016/S0140-6736(20)31022-9]

80 **Cao B**, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* 2020; **382**: 1787-1799 [PMID: 32187464 DOI: 10.1056/NEJMoa2001282]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 31, 2020

**First decision:** September 29, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Gupta V, Sonntag R, Thomann S **S-Editor:** Wang JL **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Simplified algorithm for endoscopic management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic.** IBD: Inflammatory bowel disease; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.



**Figure 2 Simplified algorithm for surgical management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic.** IBD: Inflammatory bowel disease; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.



**Figure 3 Simplified algorithm for management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic.** IBD: Inflammatory bowel disease; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.

**Table 1 Management of inflammatory bowel disease medications during the Coronavirus disease 2019 pandemic**

|  |  |
| --- | --- |
| **Medications** | **Clinical case scenarios** |
| **Stable IBD without SARS-CoV-2 infection** | **Quiescent IBD with positive SARS-CoV-2 infection** | **Active IBD with positive COVID-19 infection (irrespective of severity)** |
| Sulfasalazine and 5-aminosalicylates | Continue therapy  | Continue therapy  | Continue therapy  |
| Budesonide  | Continue therapy  | Unclear evidence | Unclear evidence |
| Oral/Parenteral steroids | Discontinue/Delay therapy | Discontinue/Delay therapy | Discontinue/Delay therapy |
| Immunomodulators (methotrexate and thiopurines) | Continue therapy  | Discontinue/Delay therapy | Discontinue/Delay therapy |
| Anti-tumor necrosis factor inhibitors (infliximab, adalimumab, certolizumab and golimumab) | Continue therapy  | Unclear evidence | Discontinue/Delay therapy |
| Anti-integrins (vedolizumab) | Continue therapy  | Unclear evidence | Unclear evidence |
| Anti-interleukins (ustekinumab  | Continue therapy  | Unclear evidence | Discontinue/Delay therapy |
| Janus kinase inhibitors (tofacitinib) | Continue therapy  | Discontinue/Delay therapy | Discontinue/Delay therapy |

IBD: Inflammatory bowel disease; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.